Menlo Park, United States
BillionToOne, founded in 2016, is a pioneering entity in the Biotechnology and Health Care industries, headquartered in the United States. The company is renowned for its commitment to enhancing the accuracy, efficiency, and accessibility of molecular diagnostics, encapsulated in their slogan: "We push the boundaries of molecular diagnostics through quantitative technologies."
The core of BillionToOne's innovation lies in its proprietary molecular counting platform, which is capable of counting DNA molecules at the single-count level. This groundbreaking technology aims to improve disease detection and change the landscape of precision diagnostics.
Recently, BillionToOne secured a $130.00M Series D investment on 21 June 2024, demonstrating significant interest and confidence from a diverse group of investors including Civilization Ventures, Adams Street Partners, 50Y, Baillie Gifford, Hummingbird Ventures, Libertus Capital, Neuberger Berman Group, and PremjiInvest.
